Executive Committee
- Dr Jonathan Coates (Chief Scientific Officer and Interim CEO)
- Mr Stephen Kerr (Chief Financial Officer and Company Secretary)
Dr Jonathan Coates (Chief Scientific Officer and Interim CEO)
Dr Coates, who has more than 25 years experience in antiviral drug discovery in the biotechnology and pharmaceutical industries and was one of the inventors of antiviral drug, 3TC targeting HIV and HBV for Glaxo-Wellcome, will resume his previous position of Chief Scientific Officer at Avexa. He will also take up the role of interim CEO while the company conducts an independent review of the development programs and investigates its commercial options.
Mr Stephen Kerr (Chief Financial Officer and Company Secretary)
Mr Kerr received his Bachelor of Commerce from Melbourne University in 1984 and has more than 25 years experience in finance. A qualified Chartered Accountant since 1987, he is also a Fellow of the Chartered Institute of Company Secretaries of Australia. Mr Kerr commenced his career in chartered accounting before moving into the corporate environment. He has held senior finance and company secretarial positions with a number of public and private companies in Australia and New Zealand including Freightways Limited (NZ) and the formerly ASX listed Ausdoc Group Limited. Mr Kerr has extensive experience in finance, corporate governance, merger and acquisition transactions and capital raisings. Mr Kerr joined Avexa in March 2009 and holds the position of Chief Financial Officer and Company Secretary.
